Comparable Cellular Immune Responses in Patients with and without Antiretroviral Treatment after Immunization with HIV-1 P24, P17 and Tat Consensus Peptides (Vacc-5q)
- *Corresponding Author:
- Anne-Marte Bakken Kran
Ullevål Department of Microbiology
Oslo University Hospital
Ullevål, N-0407 Oslo, Norway
Tel: +47 22 11 85 04/+47 22 11 88 45
Fax: +47 22 11 88 42
E-mail: [email protected]
Received Date: February 14, 2014; Accepted Date: March 29, 2014; Published Date: April 10, 2014
Citation: Kran AMB, Lind A, Sommerfelt MM, Baksaas I, Sørensen B, et al. (2014) Comparable Cellular Immune Responses in Patients with and without Antiretroviral Treatment after Immunization with HIV-1 P24, P17 and Tat Consensus Peptides (Vacc-5q). J AIDS Clin Res 5:296. doi:10.4172/2155-6113.1000296
Copyright: © 2014 Kran AMB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objectives: Therapeutic vaccination in chronic HIV-infection aims to attenuate disease progression by promoting new HIV-specific T cell-clones. Most clinical trials with therapeutic vaccines are conducted on patients receiving antiretroviral therapy (ART). However, studies of vaccination in untreated individuals are limited. We present the first data from a phase I/II clinical trial with a peptide-based therapeutic vaccine (Vacc-5q) consisting of five short, modified consensus peptides from p17, p24, and Tat. In addition to evaluating safety and immunogenicity of Vacc-5q, we compared responses induced in patients on effective ART with those of ART-naïve patients.
Methods: HIV-infected patients stable on ART (n=10) and treatment naive patients (n=10) received 11 intradermal injections of Vacc-5q over 26 weeks, using GM-CSF as an adjuvant. Immunogenicity was assessed both in vivo by delayed type hypersensitivity (DTH) skin tests, and in vitro by T cell activation assays. Persistence of immune responses was retested after 3.5 years.
Results: Vacc-5q was found to be immunogenic. Specific T cell-responses both in vivo and in vitro increased significantly from baseline to week 4 (p<0.01), and were still present after 3.5 years. No significant differences were observed between ART treated and ART naïve patients at any time point.
Conclusion: Vacc-5q induced potent HIV associated cellular immune responses both in ART treated and in treatment-naïve viremic patients. These responses were comparably strong in both study arms and still present after 3.5 years, indicating that suppression of plasma viral load by ART might not be essential for optimal immunization.